Hi
@Davisite,
Thanks for the article. I just had a quick read. Interesting in respect to what PIQ’s new Patent in drug development in Kidney disease granted in the USA, ANN’d some time ago, also PromarkerD.
Here’s a related article:
https://www.fiercebiotech.com/biote...t-diabetic-kidney-disease-109m-goldfinch-deal
Interestingly enough, this company Goldfinch are targeting FSGS & NASH in their own pipeline as well as this deal on genomic mapping & a genomic mapping in DKD. I am also invested in DXB whom PIQ have partnered with in Ph2b trials & interestingly enough, we are in trials now for DKD & FSGS. Some time ago, we had a NASH targeting drug also in pipeline development, but in the pipeline is now ‘undisclosed’, & all drugs identified by HIT Receptor technology & IP on both. Previously they were licensing out HIT Receptor & now not. A very long cross over dual trials & so you can understand SP.
2 little Aussie Biotechs who are in later stages of development with good IP, whom both have been rather quiet lately. 2b for DXB & I’m sure they will want to know this information too.
I see you haven’t bought here yet, but I & others appreciate your thoughts & respect your posts, some other boards I have read, BIT maybe not, but this is a completely different clinical area. Well when you get the time,
@Davisite. Thanks again as relevant & will generate some interesting discussion at the least
. I better go pop over to DXB & share the articles. Best wishes all.
(20min delay)